Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Amylin
More »

  • Creative Acquisition in Biotech, Take Two
    ... Eight of these companies were among the 10 largest in 2011. Amylin Pharmaceuticals, ninth largest in 2011, was acquired by Bristol-Myers Squibb in 2012. ViroPharma, which was the ...
    8-1-2013
  • Top 15 Job-Cutting Companies of 2013 (So Far)
    ... the end of 2014. The jobs were created by Amylin Pharmaceuticals, which was headquartered ... Why the company did it: Consolidation of operations following Amylin acquisition, as well ...
    7-11-2013
  • GEN | Biolinks
    AltheRx Pharmaceuticals Altravax Amarin Ambit Biosciences Ambrx Ambry Genetics Amgen Amicus Therapeutics Amnis Amplimmune Amresco Amunix Amylin Pharmaceuticals Anaphore Anaspec ...
  • BMS Shores Up R&D after Trial Failure, Plavix Patent Loss
    ... operations it acquired last summer when it bought diabetes drug pioneer Amylin Pharmaceuticals, saying the shutdown would improve BMS' efficiency and eliminate redundant jobs. ...
    4-8-2013
  • Scaling Up Peptide Drugs
    adults with short bowel syndrome; and Bydureon (an extended-release version of Byetta, with the active ingredient exenatide, Amylin/Alkermes) for patients with type 2 diabetes. ...
    4-1-2013
  • Lilly Ends Phase III Rheumatoid Arthritis Program
    $490 million of deferred exenatide-related income, hinging upon the company transferring commercial rights to the type 2 diabetes drug exenatide outside the U.S. to Amylin. ...
    2-7-2013
  • Biggest Biotech Trends of 2012
    Squibb (BMS) to commercialize Amylin Pharmaceuticals' portfolio, in return for ... BMS expanded its reach in diabetes when it acquired Amylin for $7 billion in August. Weeks ...
    1-15-2013
  • Top 25 M&A Deals of 2012
    ... Acquired by: Hologic Price: $3.8 billion Deal Completed: Aug. 1 Premium: 20% #3. Amylin Pharmaceuticals Acquired by: Bristol-Myers Squibb Price: $5.3 billion 10 Deal ...
    1-4-2013
  • Biggest Biotech Trends of 2012
    Squibb (BMS) to commercialize Amylin Pharmaceuticals' portfolio, in return for ... BMS expanded its reach in diabetes when it acquired Amylin for $7 billion in August. Weeks ...
    12-26-2012
  • Biotech: A Model of Creative Acquisition
    ... but not for 2005. Those six companies-Vertex, Alexion, Cubist, United Therapeutics, Amylin, and ViroPharma-reported total revenues of $0.67 billion for 2005, increasing around ...
    12-1-2012
  • The 10 Most Well-Connected People in Biotech
    ... Faculty Development Program, national program director; trustee emeritus, 1980-present Amylin Pharmaceuticals, Board of Directors, 2005-present Elixir Pharmaceuticals, Chairman, ...
    10-29-2012
  • Falling Off The Patent Cliff: AZ, Sanofi Post Disappointing Results
    Seroquel accounted for a 19% drop in U.S. revenues, which otherwise rose by nearly 6%, including $44 million from AZ's share of the Amylin diabetes portfolio acquired in August. ...
    10-25-2012
  • AZ Names Roche Executive as New CEO
    of Amylin Pharmaceuticals' portfolio of products, in return for AZ paying BMS about $3.4 billion cash. The arrangement was part of BMS' $7 billion acquisition of Amylin, a ...
    8-28-2012
  • Fearing Anchors Away After M&A
    Across the country in San Diego, two bioanchors are no more: Amylin Pharmaceuticals got ... In addition to Amylin and Gen-Probe, Ardea Biosciences, whose experimental gout drug ...
    8-20-2012
  • Top 25 Biotech Companies
    Cap: $2.10 billion (7/29: 63,544,578 shares * price $32.98) % Change: 141.0% #18. Amylin Pharmaceuticals 1,2 2012 Market Cap: $5.06 billion (7/27: 164,283,038 shares * price ...
    8-17-2012
  • More »

    Journal Articles

  • Amylin Competes for Binding Sites of CGRP in the Chamber Angle...
    Päivi Alajuuma, Olli Oksala, Hannu Uusitalo
    Journal of Ocular Pharmacology and Therapeutics
    Amylin Competes for Binding Sites of CGRP in the Chamber Angle and Uvea of Monkey, Cat, ... Furthermore, rat amylin clearly displaced CGRP binding from ciliary muscle and ciliary ...
  • Adjunctive Therapy with the Amylin Analogue Pramlintide Leads...
    Robert E. Ratner, Laura L. Want, Mark S. Fineman, Maggie J. Velte, James A. Ruggles, Alan Gottlieb, Christian Weyer, Orville G. Kolterman
    Diabetes Technology & Therapeutics
    Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in ... The objective of this study was to assess the effect of mealtime amylin replacement with ...
  • Unresolved Challenges with Insulin Therapy in Type 1 and Type...
    S. V. Edelman, C. Weyer
    Diabetes Technology & Therapeutics
    Diabetes: Potential Benefit of Replacing Amylin, a Second β -Cell Hormone Diabetes ... Amylin is a second ß-cell hormone that is cosecreted with insulin in response to meals, ...
  • Development and Characterization of Monoclonal Antibodies Specific...
    J.L. PHELPS, E.K. BLASE, J.E. KODA
    Hybridoma
    Development and Characterization of Monoclonal Antibodies Specific for Amylin Hybridoma

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll